Glenn Crater
Chief Medical Officer Innospera Pharma
Dr. Glenn Crater is a board-certified pulmonologist and physician executive with over 25 years of clinical experience and more than 20 years in drug and device development across respiratory, metabolic, renal, neurological, dermatological, gastrointestinal, and orphan diseases. He has led pivotal programs including the Phase III development and U.S. launch of YUPELRI and ANORO for COPD, and the global approval of NIOX VERO for monitoring exhaled nitric oxide, including pediatric and diagnostic indications.
Dr. Crater also contributed to Inversago Pharma’s Phase Ib program, which supported its $1B acquisition by Novo Nordisk, and has held senior leadership roles including Country Medical Director for GSK Canada.
As Chief Medical Officer at Innospera Pharma, he is advancing ING-006, a novel GPR84/GPR40 modulator for idiopathic pulmonary fibrosis and related diseases, leveraging his expertise in translational development, fibrotic disease biology, and clinical strategy to bring next-generation therapies to patients.
Seminars
- Has the Approval of New Antifibrotics Fundamentally Changed IPF Trial Design? Exploring whether the introduction of additional approved therapies requires a paradigm shift toward combination trials and active comparators, or whether traditional development approaches remain valid
- Managing Background Therapies in an Evolving Standard of Care Debating strategies for incorporating monotherapy, prior antifibrotic exposure, and real-world combination regimens without compromising interpretability or feasibility of clinical trials.
- Lessons from Other Crowded Therapeutic Areas Considering how fields such as inflammatory bowel disease, rheumatoid arthritis, and psoriasis have continued drug development despite multiple approved therapies, and whether ILD should follow a similar path.
- Designing Future Trials as the Pipeline Expands Anticipating how additional approvals may influence eligibility criteria, stratification strategies, and expectations for head-to-head or combination studies.
